Acrux Limited

A$0.01As of Sun 8 Nov 2026, 12:00 UTC

ASX:ACRHealthcare

Country Australia

PE (Fwd) •••

TSR 10Y CAGR (30.40%)

Div yield —

ROE (48.51%)

Biotechnology

Beta (5Y) 0.99

PE TTM —

TSR TTM (35.71%)

Mkt cap A$5.307M

ROIC (8.86%)

SE Grade™

—

Value

Quality

Moat

Consensus

Reference

$0.0105

16.57%

(21.05%)

Hold 5|3|12|9|5

TTM

FYE 30 Jun AUD

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

5Y

10Y

Peers

0.191

Revenue$M

1.670

1.748

1.804

1.899

1.940

1.972

2.035

2.106

2.216

2.272

0.202

3.21%

3.44%

64

29.72

Revenue growth%

15.50

15.89

17.28

16.53

15.37

15.08

13.50

15.11

17.46

20.46

24.28

15.11

15.69

62

28.11

Gross margin%

9.20

11.44

13.69

10.87

11.47

11.35

10.03

8.63

8.26

5.68

29.09

8.63

10.45

61

11.82

Operating margin%

24.04

26.42

28.74

27.34

26.96

28.59

26.62

27.98

30.05

30.77

4.96

28.59

27.66

44

28.49

Net margin%

27.78

27.72

30.09

32.40

34.58

34.82

34.30

32.21

32.50

32.50

29.34

32.50

32.45

71

18.64

P/E ratio (avg)x

12.09

12.05

11.08

9.548

10.00

9.635

8.470

8.277

8.191

8.684

33.05

8.470

9.591

65

14.06

EV/EBITx

32.97

31.71

31.59

33.04

38.71

40.35

38.28

37.80

42.68

40.36

31.13

40.35

38.04

78

27.72

FCF yield (avg)%

24.26

23.22

20.31

18.59

21.16

20.24

22.12

24.34

23.63

26.23

2.19

23.63

22.67

51

23.64

FCF margin%

24.79

25.99

27.56

26.49

26.18

26.76

29.49

29.84

28.39

26.57

14.91

28.39

26.66

35

0.113

FCF / Net incomex

1.128

1.042

1.155

1.129

1.089

1.087

1.085

1.193

1.116

1.245

1.300

1.116

1.122

81

16.52

ROIC%

11.05

10.39

11.47

10.46

9.00

9.59

9.06

6.32

5.50

4.09

18.55

6.32

9.32

34

16.69

Return on equity%

10.56

8.62

10.83

9.06

8.62

10.84

10.05

7.49

6.68

5.67

9.71

7.49

8.84

18

20.15

Return on assets%

1.15

0.40

1.76

0.95

3.14

1.81

1.31

3.47

2.93

4.45

11.23

2.93

1.79

9

—

EPS$

—

—

—

—

—

—

—

—

—

—

—

1.14%

0.01%

—

19.26

EPS growth%

4.43

5.99

3.91

2.15

0.82

2.01

0.40

0.40

0.40

0.40

22.64

0.40

1.42

58

—

Bookvalue per sh$

—

—

—

—

—

—

—

—

—

—

—

9.86%

7.52%

—

—

FCF per share$

—

—

—

—

—

—

—

—

—

—

—

(1.44%)

(0.12%)

—

—

Dividend per sh$

—

—

—

—

—

—

—

—

—

—

—

4.52%

6.65%

—

5.62

Div yield (avg)%

18.44

17.01

17.01

18.88

19.86

21.64

21.78

20.01

22.30

20.67

25.23

21.64

19.94

93

24.98

Payout ratio%

23.23

24.00

21.80

20.27

22.75

25.15

28.00

28.77

28.97

31.48

26.83

28.77

24.57

69

0.581

Shares (diluted)B

0.838

0.926

1.048

1.099

1.162

1.286

1.485

1.718

1.968

1.928

0.603

10.65%

9.97%

64

19.37

Buyback yield%

9.06

8.13

10.92

9.61

7.89

9.02

6.11

3.68

4.23

5.58

25.72

5.58

8.01

76

0.681

D/E ratiox

0.781

0.817

0.782

0.857

0.817

0.904

0.966

0.983

0.975

0.958

0.426

0.966

0.880

23

1.759

Enterprise value$M

1.511

1.575

1.432

1.580

1.509

1.634

1.528

1.528

1.630

1.710

0.295

2.52%

0.66%

70

1.109

LT debt$M

1.760

1.927

2.137

2.148

2.253

2.301

2.150

2.083

2.333

2.283

1.105

0.27%

2.26%

41

Peers (US$3.645M)

Cap (US$)

PE

Zelira Therapeutics…

4.086M

—

Bio-Gene Technology…

3.911M

—

Biotron Limited

3.826M

—

Strategic Partners A/S

3.638M

18.36x

Capital

TTM

5Y

10Y

Leveragex

0.316

0.397

0.288

EBIT/Intx

0.963

0.280

0.293

Own earn%

(306.99)

3.28

5.25

Sh yield%

24.99

26.53

27.63

Owners

Insiders/Inst%

1.96

31.47

Short interest%

1.04

SBC / revenue%

0.95

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

4

Op margin range%

24–31

$1 testx

0.0

Incr. ROIC%

4

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

$2.272M

3.44%

1.00×

Cost of revenue

$1.034M

3.86%

1.04×

Operating expenses

$0.552M

3.10%

0.97×